Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Retatrutide Sexual Function Impact: What the Phase 2 Data Actually Show At a glance Drug / retatrutide (LY3437943), investigational triple GIP/GLP-1/glucagon receptor agonist Phase 2 trial / Jastreboff et al., NEJM 2023, N=338 adults with obesity Peak weight loss / 24.2% mean body-weight reduction at 48 weeks (12 mg dose) Sexual-function endpoints / not prespecified in Phase 2
mBio 5 , e00889, doi:10.1128/mBio.00889-14 (2014)
Belles website states that compounded medications are not FDA approved, and the clinic does not carry oral compounded GLP-1 options, which, like compounded medications, may vary in efficacy
It worsens nausea, contributes to dehydration, impairs fat metabolism, and provides empty calories
That's enough to reap ample health benefits, like losing inches around your middle, which means less harmful visceral fat known as belly fat
